Quality of life, efficacy, and patient-reported outcome with NEPA as antiemetic prophylaxis in patients receiving highly or moderately emetogenic chemotherapy

被引：0
|
作者：
Karthaus, M. [1 ]
Rauh, J. [1 ]
Guth, D. [1 ]
Heilmann, V. [1 ]
Schilling, J. [1 ]
机构：
[1] Stadt Klinikum Munchen Harlaching, Klin Hamatol Onkol & Palliat Med, Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1506TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] NEPA as antiemetic prophylaxis in cancer patients receiving highly or moderately emetogenic chemotherapy: Patient-reported quality of life and efficacy
    Karthaus, M.
    Rauh, J.
    Guth, D.
    Heilmann, V
    Schilling, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 293 - 293
  • [2] Quality of Life, Efficacy and Patient-Reported Outcome With NEPA as CINV Prophylaxis in Highly or Moderately Emetogenic Chemotherapy
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (08) : 9 - 10
  • [3] Efficacy of NEPA as antiemetic prophylaxis in breast cancer patients receiving highly or moderately emetogenic chemotherapy - Interim results of a German prospective, non-interventional study
    Schilling, J.
    Hielscher, C.
    Hanusch, C.
    Kurbacher, C.
    Busch, S.
    Karthaus, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [4] Antiemetic prophylaxis with NEPA in patients with moderately emetogenic chemotherapy - quality of life and efficacy data from the interims analysis of a prospective non-interventional study
    Karthaus, M.
    Kuhn, T.
    Jungberg, P.
    Klenske, J.
    Hollaender, M.
    Schilling, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 12 - 13
  • [5] Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy
    Martin Chasen
    Laszlo Urban
    Ian Schnadig
    Bernardo Rapoport
    Dan Powers
    Sujata Arora
    Rudolph Navari
    Lee Schwartzberg
    Cesare Gridelli
    Supportive Care in Cancer, 2017, 25 : 85 - 92
  • [6] Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy
    Chasen, Martin
    Urban, Laszlo
    Schnadig, Ian
    Rapoport, Bernardo
    Powers, Dan
    Arora, Sujata
    Navari, Rudolph
    Schwartzberg, Lee
    Gridelli, Cesare
    SUPPORTIVE CARE IN CANCER, 2017, 25 (01) : 85 - 92
  • [7] Quality of life under and efficacy of NEPA as CINV prophylaxis in patients with gastrointestinal cancer receiving highly or moderately emetogenic chemotherapy -Results of a German prospective non-interventional study
    Karthaus, M.
    Oskay-Oezcelik, G.
    Zahn, M. -O
    Haas, S.
    Kuhn, T.
    Schilling, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 213 - 213
  • [8] NEPA as CINV prophylaxis in highly or moderately emetogenic chemotherapy - Results of a German prospective non-interventional study on quality of life and efficacy
    Schilling, J.
    Guth, D.
    Heilmann, V.
    Klare, P.
    Karthaus, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 165 - 166
  • [9] Quality of life and efficacy of NEPA as CINV prophylaxis in highly or moderately emetogenic chemotherapy - interim results of a German prospective non-interventional study
    Karthaus, M.
    Schilling, J.
    Rauh, J.
    Heilmann, V.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 184 - 184
  • [10] ANTIEMETIC EFFICACY OF PALONOSETRON IN CHILDREN RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY: PRELIMINARY RESULTS
    Varrasso, G.
    De Grazia, A.
    Mollace, M. G.
    Megaro, G.
    Paiano, M.
    Suraci, S.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 174 - 174
12345